GenVec, Inc.
From EverybodyWiki Bios & Wiki
| GenVec | |
| Public company | |
| Traded as | NASDAQ: GNVC |
| ISIN | 🆔 |
| Industry | Pharmaceuticals |
| Founded 📆 | 1992 |
| Founder 👔 | |
| Headquarters 🏙️ | Gaithersburg, Maryland, U.S. |
Area served 🗺️ | |
Key people | Douglas J. Swirsky, President and CEO |
| Products 📟 | CGF166Clinical trial#Phase 1/2 |
 | |
| Members | |
Number of employees | 13 |
| 🌐 Website | www.genvec.com |
| 📇 Address | |
| 📞 telephone | |
GenVec, Inc. (NASDAQ: GNVC) is a biopharmaceutical company working to build a pipeline of therapeutics and vaccines based on its adenovector technology platform that can realize the promise of gene-based medicine. The company's lead product candidate for hearing loss and balance disorders, partnered with Novartis, is in a first-in-man gene delivery Phase 1/2 clinical trial in patients with severe to profound hearing loss. GenVec therapeutics and vaccines have been administered to over 3,000 clinical study subjects.
References[edit]
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help EverybodyWiki by expanding it. |
This article "GenVec" is from Wikipedia. The list of its authors can be seen in its historical. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
Categories:
- Biotechnology companies of the United States
- Pharmaceutical companies of the United States
- Companies based in Gaithersburg, Maryland
- Health care companies based in Maryland
- Companies listed on NASDAQ
- 1992 establishments in Maryland
- Pharmaceutical companies established in 1992
- Biotechnology companies established in 1992
- Medical company stubs
